The role of teriflunomide in Multiple Sclerosis patient: an observational study

References

• Amato, M. P., Bartolozzi, M., Zipoli, V., Portaccio, E., Mortilla, M., Guidi, L., Siracusa, G., Sorbi, S., Federico, A., & De Stefano, N. (2004). Neo-cortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment. Neurology, 63(1), 89–93. https://doi.org/10.1212/01.WNL.0000129544.79539.D5
   PubMed Web of Science ®Google Scholar
• Amato, M. P., Hakiki, B., Goretti, B., Rossi, F., Stromillo, M. L., Giorgio, A., Roscio, M., Ghezzi, A., Guidi, L., Bartolozzi, M. L., Portaccio, E., & De Stefano, N. (2012). Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology, 78(5), 309–314. https://doi.org/10.1212/WNL.0b013e31824528c9
   PubMed Web of Science ®Google Scholar
• Amato, M. P., Portaccio, E., Goretti, B., Zipoli, V., Battaglini, M., Bartolozzi, M. L., Stromillo, M. L., Guidi, L., Siracusa, G., Sorbi, S., Federico, A., & De Stefano, N. (2007). Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Archives of Neurology, 64(8), 1157–1161. https://doi.org/10.1001/archneur.64.8.1157
   PubMedGoogle Scholar
• Amato, M. P., Razzolini, L., Goretti, B., Stromillo, M. L., Rossi, F., Giorgio, A., Hakiki, B., Giannini, M., Pasto, L., Portaccio, E., & De Stefano, N. (2013). Cognitive reserve and cortical atrophy in multiple sclerosis: A longitudinal study. Neurology, 80(19), 1728–1733. https://doi.org/10.1212/WNL.0b013e3182918c6f
   PubMed Web of Science ®Google Scholar
• Brassington, J. C., & Marsh, N. V. (1998). Neuropsychological aspects of multiple sclerosis. Neuropsychology Review, 8(2), 43–77. https://doi.org/10.1023/A:1025621700003
   PubMed Web of Science ®Google Scholar
• Cole, J. H., Jolly, A., De Simoni, S., Bourke, N., Patel, M. C., Scott, G., & Sharp, D. J. (2018). Spatial patterns of progressive brain volume loss after moderate-severe traumatic brain injury. Brain, 141(3), 822–836. https://doi.org/10.1093/brain/awx354
   PubMedGoogle Scholar
• De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H., & Kieseier, B. C. (2014). Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs, 28(2), 147–156. https://doi.org/10.1007/s40263-014-0140-z
   PubMed Web of Science ®Google Scholar
• Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., DeLuca, G., De Stefano, N., Erickson, B. J., Evangelou, N., Fazekas, F., Geurts, J. J., Lucchinetti, C., Miller, D. H., Pelletier, D., Popescu, B. F. G., & Lassmann, H. (2012). The attendees of the correlation between pathological MRI findings in MS workshop association between pathological and MRI findings in multiple sclerosis. The Lancet Neurology, 11(4), 349–360. https://doi.org/10.1016/S1474-4422(12)70003-0
   PubMed Web of Science ®Google Scholar
• Filippi, M., Rocca, M. A., Horsfield, M. A., Hametner, S., Geurts, J. J. G., Comi, G., & Lassmann, H. (2013). Imaging cortical damage and dysfunction in multiple sclerosis. JAMA Neurology, 70(5), 556–564. https://doi.org/10.1001/jamaneurol.2013.1954
   PubMed Web of Science ®Google Scholar
• Gajofatto, A., & Benedetti, M. D. (2015). Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? World Journal of Clinical Cases: WJCC, 3(7), 545. https://doi.org/10.12998/wjcc.v3.i7.545
   PubMed Web of Science ®Google Scholar
• Hildebrandt, H., & Schwendemann, G. (2004). Kognitive Beeinträchtigungen bei Multipler Sklerose. In A. Zieger & P. Schönle (Eds.), Neurorehabilitation bei diffuser Hirnschädigung. Hippokampus (pp. 237–278). Bad Honnef.
   Google Scholar
• Maghzi, A. H., Revirajan, N., Julian, L. J., Spain, R., Mowry, E. M., Liu, S., Jin, C., Green, A. J., McCulloch, C. E., Pelletier, D., & Waubant, E. (2014). Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Multiple Sclerosis and Related Disorders, 3(6), 720–727. https://doi.org/10.1016/j.msard.2014.07.003
   PubMed Web of Science ®Google Scholar
• Miller, A., O'Connor, P., Wolinsky, J., Confavreux, C., Comi, G., Kappos, L., … & Freedman, M. (2011, October). Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase III trial (TEMSO). In MULTIPLE SCLEROSIS JOURNAL, 17, S182–S182. ENGLAND: SAGE PUBLICATIONS LTD.
   Google Scholar
• Miller, A. E. (2017). Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: Clinical evidence and long-term experience. Therapeutic Advances in Neurological Disorders, 10(12), 381–396. https://doi.org/10.1177/1756285617722500
   PubMed Web of Science ®Google Scholar
• Oh, J., & O’Connor, P. W. (2014). Teriflunomide in the treatment of multiple sclerosis: Current evidence and future prospects. Therapeutic Advances in Neurological Disorders, 7(5), 239–252. https://doi.org/10.1177/1756285614546855
   PubMed Web of Science ®Google Scholar
• Patti, F., De Stefano, M., Lavorgna, L., Messina, S., Chisari, C. G., Ippolito, D., Lanzillo, R., Vacchiano, V., Realmuto, S., Valentino, P., Coniglio, G., Buccafusca, M., Paolicelli, D., D’Ambrosio, A., Montella, P., Brescia Morra, V., Savettieri, G., Alfano, B., Gallo, A., Simone, I., & Wylie, G. (2015). Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients. Plos One, 10(3), e0120754. https://doi.org/10.1371/journal.pone.0120754
   PubMed Web of Science ®Google Scholar
• Radue, E. W., Sprenger, T., Gaetano, L., Mueller-Lenke, N., Cavalier, S., Thangavelu, K., Panzara, M. A., Donaldson, J. E., Woodward, F. M., Wuerfel, J., Wolinsky, J. S., & Kappos, L. (2017). Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurology - Neuroimmunology Neuroinflammation, 4(5), e390. https://doi.org/10.1212/NXI.0000000000000390
   PubMed Web of Science ®Google Scholar
• Rao, S. M., & the Cognitive Function Study Group of the National Multiple Sclerosis Society. (1990). A manual for the Brief Repeatable Battery of Neuropsychological Tests in multiple sclerosis. Medical College of Wisconsin: Milwaukee, WI.
   Google Scholar
• Tanasescu, R., Evangelou, N., & Constantinescu, C. S. (2013). Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment, 9, 539. https://doi.org/10.2147/NDT.S31248
   PubMed Web of Science ®Google Scholar
• Vollmer, T., Huynh, L., Kelley, C., Galebach, P., Signorovitch, J., DiBernardo, A., & Sasane, R. (2016). Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: A systematic literature review. Neurological Sciences, 37(2), 165–179. https://doi.org/10.1007/s10072-015-2400-1
   PubMed Web of Science ®Google Scholar
• Zivadinov, R., Jakimovski, D., Gandhi, S., et al. (2016). Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert review of neurotherapeutics, 16(7), 777–793.
   PubMed Web of Science ®Google Scholar